5α-reductase (SRD5A2) is required for converting progesterone into allopregnanolone.

The claim that 5α-reductase (including SRD5A2 activity) is required for the conversion of progesterone to allopregnanolone, and that reduced 5α-reduction activity lowers the efficiency of this conversion, is well-supported by biochemical and clinical research.

Clinical and effectiveness evidence

The synthesis of allopregnanolone from progesterone is a two-step process where 5α-reductase activity serves as the primary rate-limiting factor.

• Pharmacological Evidence: Studies on 5α-reductase inhibitors (5ARIs), such as finasteride and dutasteride, consistently show that blocking this enzyme significantly reduces allopregnanolone levels in both plasma and cerebrospinal fluid. Even when progesterone levels remain stable or increase, the inhibition of the 5α-reductase enzyme prevents the substrate from being converted into its downstream neurosteroid metabolites.
• Metabolic Ratios: Research into the allopregnanolone-to-progesterone ratio confirms that the efficiency of this conversion is directly dictated by 5α-reductase activity. In clinical settings where 5α-reductase is inhibited or naturally lower, the production of allopregnanolone from a fixed amount of progesterone is proportionally diminished.

Mechanistic explanations

The biological pathway follows a specific enzymatic sequence that is critical for neurosteroidogenesis:

• Step 1: Progesterone to 5α-DHP: The enzyme 5α-reductase (including the SRD5A2 isoform) performs a stereospecific reduction of the Δ⁴ double bond in progesterone to form 5α-dihydroprogesterone (5α-DHP). SRD5A2 is known to have a high affinity for progesterone, making it a key driver of this initial step.
• Step 2: 5α-DHP to Allopregnanolone: The intermediate 5α-DHP is then acted upon by 3α-hydroxysteroid dehydrogenase (3α-HSD), which reduces the 3-keto group to a 3α-hydroxy group, creating allopregnanolone (3α,5α-tetrahydroprogesterone).
• Rate-Limiting Nature: Because 5α-reductase is the first and slowest enzyme in this sequence, its activity levels determine the "throughput" of the entire pathway. If 5α-reductase activity is reduced—whether through genetic variants (such as the SRD5A2 V89L polymorphism), pharmacological inhibition, or physiological shifts—the total amount of allopregnanolone generated from a given pool of progesterone will decrease.

Bottom line

The evidence robustly supports the claim: 5α-reductase (including SRD5A2) is the essential, rate-limiting enzyme for converting progesterone into 5α-dihydroprogesterone, which is then converted to allopregnanolone. Consequently, any reduction in 5α-reductase activity will lower the production of allopregnanolone from a specific level of progesterone.